市場調查報告書
商品編碼
1029142

院內感染疾病治療藥的全球市場 (2021-2026年):產業趨勢、市場佔有率、市場規模、成長預測、市場機會

Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 141 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球院內感染疾病治療藥的市場規模2020年記錄約110億美元的規模。

院內感染增加,老年人口增加,醫院等醫療機關的衛生環境惡化等要素促進該市場的成長。還有先進微生物來源的傷口護理藥物、敷料、疫苗的開發等,各種產品革新發展,促進市場成長。其他如廣泛的R&D活動和醫療基礎設施的改善等要素也推動市場進一步成長。

本報告提供全球院內感染疾病治療藥的市場調查,市場定義和概要,價值鏈,新型冠狀病毒感染疾病 (COVID-19)以及其他的市場影響因素分析,市場規模的變化、預測,藥物類型、適應症、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 序文

第2章 調查範圍、調查手法

第3章 摘要整理

第4章 簡介

第5章 世界市場趨勢

  • 市場概要
  • 市場成果
  • COVID-19的影響

第6章 市場分析、預測:各藥物類型

  • 抗菌藥
  • 抗真菌藥物
  • 抗病毒藥物
  • 其他

第7章 市場分析、預測:各適應症

  • 血液感染
  • 泌尿道感染
  • 手術部位感染疾病
  • 肺炎
  • 其他

第8章 市場分析、預測:各地區、主要國家

  • 北美
  • 亞太地區
  • 歐洲
  • 南美
  • 中東、非洲

第9章 SWOT分析

第10章 價值鏈分析

第11章 波特的五力分析

第12章 價格分析

第13章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Allergan Plc(AbbVie Inc.)
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG(Roche Holding AG)
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
目錄
Product Code: SR1020F92_Report

The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020. Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.

The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug type and indication.

Breakup by Drug Type:

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Breakup by Indication:

  • Blood Stream Infections
  • Urinary Tract Infections
  • Surgical Site Infections
  • Pneumonia
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S. Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the indication?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hospital infection therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2020
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2020
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2021-2026
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players